Enhancing Clinical Utility of AI Models in Polycystic Ovary Syndrome (PCOS): Integrating Staged Modelling with uncertainty aware Triage and Conformal Prediction for Cost-Efficient Risk Stratification

Adewale Alex Adegoke[1], Idris Babalola [2]*, Peter Adebayo Odesola [3]

[1] Westminster Foundation for Democracy London, United Kingdom

[2] Department of Health and Social Care, London, United Kingdom

[3] Southampton Solent University, Southampton, United Kingdom

Corresponding Author*: eidreiz01@gmail.com
ORCID Author 1: 0009-0006-2397-0263, ORCID Author 2: 0009-0007-5531-6909, ORCID Author 3: 0009-0008-5648-1524

Abstract

In this study we develop a deployable, cost-aware pipeline for PCOS risk stratification that unifies staged modelling, calibration, decision-theoretic evaluation and uncertainty-aware prediction. Stage 1 models use low-cost clinical variables for screening, while Stage 2 augments these with confirmatory laboratory and ultrasound features. We evaluate accuracy, discrimination and uncalibrated probability quality (AUC, Accuracy, F1, Precision, Recall, Brier, ECE) alongside clinical utility via decision curve analysis (DCA) and we embed conformal prediction to provide finite-sample coverage guarantees and controlled abstention.

Held-out and out-of-fold (OOF) results show clear gains from Stage 1 to Stage 2 for both Logistic Regression (LR) and Random Forest (RF). On OOF estimates, AUC rose from 87.60% to 94.47% (LR) and 88.57% to 96.00% (RF). LR generally exhibited better raw calibration (lower ECE and in most settings, lower Brier), whereas RF achieved the highest precision, particularly in Stage 2. DCA indicated higher net benefit for Stage 2 across clinically relevant thresholds (≈0.15-0.35). Feature sensitivity analyses showed that retaining a compact subset of inexpensive predictors preserved ≥90% of maximal AUC, supporting cost-efficient deployment. Conformal prediction achieved 94.5% overall coverage with 41.3% abstention, maintaining near-nominal validity across age and BMI strata while appropriately increasing abstention in data-sparse subgroups.

We further evaluated capacity-constrained triage policies. Under tight capacity, risk-top-K selection maximised net benefit; as capacity increased, policy performance converged, with uncertainty-aware selection offering a safety mechanism by deferring low-confidence cases. Collectively, the framework advances PCOS AI from accuracy-centric reporting to clinically aligned, resource-aware and uncertainty-informed decision support.

Keywords: PCOS, risk stratification, staged modelling, cost-efficient diagnostics, uncertainty quantification, conformal prediction, uncertainty-aware triage, decision curve analysis, calibration, logistic regression, random forest, clinical utility.

1.0 Introduction

1.1 Background & Motivation

Polycystic ovary syndrome (PCOS) stands as the most common endocrine disorder affecting reproductive-aged women worldwide, with prevalence estimates ranging from 4% to 21% in earlier studies, depending on diagnostic criteria used [1] (Lizneva et al. 2016). Later investigations have reported higher estimates ranging 5% to 26% [2] (D'Souza Pramila et al 2022). This trend demonstrates the increasing attention of the condition and investigation into the global burden of PCOS. In some regions, more recent figures indicate that 8% to 13% of this population may be affected [3] (Tay et al. 2023). The syndrome is a leading cause of anovulatory infertility, accounting for over 75% of cases related to ovulation disorders [4] (Ghafari et al. 2025). Beyond reproductive health, PCOS is associated with significant metabolic and cardiometabolic risks, including insulin resistance, type 2 diabetes, obesity and cardiovascular disease [5] Long et al. (2022) [6] (Hussein et al. 2024). These comorbidities threaten long-term individual health and also place considerable socioeconomic burden on healthcare systems. Additionally, delayed diagnosis often as a result of heterogeneous symptom profiles and limitations of conventional diagnostic criteria restrains early intervention strategies aimed at mitigating long-term outcomes [2] (D'Souza Pramila et al 2022). Accurate and timely risk stratification in PCOS is therefore paramount. An effective predictive framework that can swiftly identify high-risk individuals presents a critical opportunity for clinical intervention, resource optimisation and improved patient outcomes.

1.2 Gaps in research

While machine learning (ML) applications for PCOS risk prediction are growing in number, they often focus primarily on maximizing diagnostic accuracy using standard performance metrics such as AUC, precision and recall without assessing whether these models deliver meaningful clinical value. A systematic overview noted high reported performance in PCOS detection (AUCs between 73% and 100%, diagnostic accuracy up to 100% and positive predictive value

(PPV)/negative predictive value (NPV) frequently exceeding 90%) [7] (Barrera et al, 2023). However, these studies typically lack evaluations based on decision-analytic frameworks that reflect real clinical trade-offs. Moreover, existing work often neglects probabilistic calibration, critical when translating predictions into actionable risk thresholds. Methods to handle predictive uncertainty remain largely unexplored in PCOS contexts, although conformal prediction has shown promise for delivering reliable set-valued predictions in healthcare [8] Vazquez J &, Facelli JC. Likewise, decision curve analysis (DCA) which allows quantification of net clinical benefit across threshold strategies is notably absent from PCOS-focused ML studies [9] (Xu X. et al 2024).

Another important but under-addressed area is operational realism. In many clinical settings, capacity constraints limit how many patients can receive intensive evaluation or screening. Yet, prior PCOS prediction models rarely consider triage strategies under capacity limitations, which can significantly influence utility and practicality. There is limited emphasis on feature cost-efficiency; few studies assess whether omitting low-importance features compromises performance, a key consideration for low-resource implementation. Recent PCOS prediction with machine learning has progressed across three data modalities: self-reported/clinical features, electronic health records (EHRs) and imaging; yet most studies emphasize discrimination (accuracy/AUC) over calibration, decision-analytic value, or uncertainty aware deployment. In a large EHR study, [10] (Zad et al 2024). trained gradient boosting, logistic regression, SVM and random forests on 30,601 at-risk outpatients and reported AUCs of 0.87-0.91 for prevalent PCOS and 0.82-0.84 for incident PCOS, highlighting scalability to routine care but without decision curve analysis (DCA) or coverage-guaranteed uncertainty estimates.

On imaging, [11] (Suha et al 2022). built a deep-learning pipeline on ovarian ultrasound features and achieved 99.89% accuracy in a 1,000-image benchmark, demonstrating near-ceiling discrimination while leaving calibration and clinical utility assessment unexplored. A recent multi-modality study [12] (Abdelsalam, S.H. et al 2024) combined ultrasound with selected clinical

predictors and reported 98.29% validation accuracy, again focusing on accuracy gains rather than net clinical benefit or subgroup reliability. Another work by [13] (Agirsoy and Oehlschlaeger 2025) pursued "non-invasive" diagnosis from clinical plus ultrasound features, with XGBoost reaching AUC = 0.995 (Clinical+USG+AMH) and even perfect test-set performance (AUC = 1.00) on a small external set, which the authors themselves caution may reflect overfitting/data leakage, yet calibration, DCA and abstention policies were not explored.

Furthermore, several works develop patient-facing or clinician-support tools from non-invasive or questionnaire-like variables. [14] (Zigarelli et al 2022). proposed "machine-aided self-diagnostic" PCOS models from anthropometrics and symptoms to enable pre-consultation screening; they prioritized convenience and explainability but did not report probability calibration, DCA, or abstention policies. [15] (Shanmugavadivel et al 2024). used correlation-based feature selection to reduce inputs and trained LR/NB/SVM, the SVM achieved 94.44% accuracy on the clinical subset, while a VGG16 modeling pipeline on ultrasound achieved 98.29% validation accuracy again without calibration or decision-analytic evaluation. [16] (Tong et al 2025). built hormone-based diagnostic models combining AMH and steroid/estrogen panels, the logistic classifier achieved test-set ROC-AUC = 0.934 (specificity = 0.947; F1 = 0.864), while XGBoost maximized accuracy (0.905) and sensitivity (0.870), yet no calibration checks, decision curve analysis, or uncertainty aware triage were reported.

A substantial stream of studies relies on the widely used 541-patient Kerala clinical dataset [17] (the same open dataset used in our study), typically targeting binary PCOS classification with conventional metrics. [18] (Khanna et al 2023). introduced an "explainable multi-stacking" framework and reported ~98% accuracy using feature-selected clinical predictors and SHAP-based explanations, but did not assess calibration, capacity-constrained triage, or uncertainty aware abstention. [19] (Rahman et al 2024). built a web-based pipeline on the same dataset, where AdaBoost and Random Forest each reached 94% accuracy with F1 up to 0.91; despite a clear engineering contribution, calibration analysis and DCA were not performed. A comparative study by [20] (Taha et al 2025). evaluated seven supervised learners on the same Kerala PCOS dataset and reported Logistic Regression as best overall (accuracy = 91.7%, precision = 96.0%, ROC-AUC = 96.8%), but it did not assess calibration, decision-analytic utility, uncertainty, or subgroup reliability leaving open questions central to staged, cost-aware deployment and safe abstention. [21] Tiwari et al 2022. ("SPOSDS") optimized feature selection and classifiers on the same dataset and reported ~93.25% accuracy yet omitted probability calibration diagnostics and decision-analytic evaluation.

In addition, [22] (Danaei Mehr and Polat 2022) systematically compared traditional and ensemble classifiers on the Kerala dataset, underscoring the value of feature selection but again without calibration reporting or uncertainty aware triage. [23] (Bharati et al 2020). previously evaluated logistic regression and random forests on the dataset in IEEE TENSYMP, reporting ~91% accuracy but no assessment of reliability (e.g., calibration curves, Brier score) or clinical net benefit. [24] (Mohi Uddin et al 2025). examined eight traditional and ensemble models on the 541-record dataset, highlighting very high headline scores (e.g., up to 99.78% for LR/SVM in their web supplement) without external validation, calibration, decision-curve, or uncertainty aware triage, highlighting overfitting risks for clinical translation. [25] (Panjwani et al 2025). proposed an optimized stacked ensemble (WaOEL) for "early, inexpensive" PCOS screening from symptomatics, attaining accuracy = 92.8% and AUC = 0.93 on a blended low-cost feature set that included the Kaggle PCOS resource; however, the study emphasized accuracy without calibration, capacity-constrained triage, or formal error-rate control. [26] (Emara et al 2025). introduced a stacked-learning pipeline with ADASYN/SMOTE rebalancing on the same Kaggle dataset and reported 97% accuracy, but again did not quantify probability calibration, net benefit under operational caps, or coverage guarantees. Overall, prior work rarely evaluates models under capacity constraints (e.g., fixed slots for further testing), seldom implements triage policies that integrate model confidence and almost never use formal uncertainty quantification with coverage guarantees in PCOS.

Conformal prediction (CP) has emerged in clinical AI as a distribution-free framework to deliver set-valued predictions with finite-sample coverage, enabling principled abstention; however, CP has not been

incorporated into PCOS risk tools. A field primer by [27] (Angelopoulos and Bates 2022) introduced practical CP methods with coverage guarantees but did not target PCOS specifically. A clinical review [8] (Vazquez J, Facelli JC 2022) catalogued CP applications across medical areas and argued for CP to quantify per-case reliability, yet no PCOS application was identified.

Methodological elements needed to bridge research to practice such as DCA for net benefit and calibration for trustworthy probabilities also remain underused in PCOS modeling. DCA is a standard way to quantify whether model-guided action improves decisions over "treat all" or "treat none [28] (Vickers, A.J. & Elkin, E.B 2006) but PCOS studies rarely report it .Even where discrimination is strong (e.g., ultrasound or stacked clinical models), miscalibration can undermine threshold-based actionability [7] (Barrera et al, 2023), a concern not addressed in the above works.

In summary, existing PCOS prediction studies report strong discrimination and excel in accuracy across datasets and modalities but generally (i) do not adopt staged, cost-aware modeling that escalates from low-cost features to richer diagnostics with explicit calibration targets; (ii) do not compare uncertainty aware triage against risk-only or utility-only rankings under capacity limits; and (iii) do not embed conformal predictors to maintain coverage with controlled abstention across subgroups. These are the main motivation for our integrated framework for PCOS risk stratification. Our work is positioned to fill these gaps by integrating staged modeling, decision-analytic evaluation, capacity-aware triage using confidence and conformal prediction into a single deployable pipeline.

1.3 Methodological Advances Needed

To address these identified gaps, an improved methodology must combine clinical decision-theoretic evaluation, calibration, uncertainty quantification and cost-aware feature selection in a coherent workflow. Models should be assessed not only for accuracy but for clinical net benefit, using decision curve analysis (DCA). DCA helps determine whether a model-based decision is better than treating all or none, at relevant threshold probabilities and has been particularly influential in evaluating diagnostic tools [28] (Vickers, A.J. & Elkin 2006). Ensuring that predicted probabilities are well-calibrated is critical, metrics such as the Brier score and expected calibration error (ECE) help measure this. In healthcare, even well-performing classifiers can be misleading if miscalibrated, leading to harmful clinical decisions [29] (Van Calster et al., 2019).

Furthermore, embracing uncertainty aware prediction frameworks, such as conformal prediction, offers a structured way to generate prediction sets with finite-sample coverage guarantees, allowing the system to abstain when confidence is low. This approach has gained traction for its ability to improve trustworthiness and fairness in clinical AI [27] (Angelopoulos & Bates, 2022). Triage or selection policies under capacity constraints must be modelled explicitly because real-world healthcare settings often cannot screen or follow up with all patients. Developing risk- and utility-based triage protocols under fixed caps ensures models are evaluated in a realistic operational context. In addition, assessing feature cost-efficiency via feature importance and drop-sensitivity analysis helps identify minimal input sets that maintain performance. This is essential when deploying AI tools in settings where data collection is expensive or limited, such as low-resource clinics.

1.4 Research Question

This study is guided by three core research questions that together address performance, operational feasibility and safety in AI-assisted PCOS risk prediction:

1. How can a staged AI modelling framework, starting with low-cost clinical features and escalating to richer diagnostics, improve predictive accuracy for PCOS and calibration in clinical risk prediction while maintaining cost-efficiency?
2. To what extent can uncertainty aware triage strategies outperform conventional risk-based and utility-based approaches in maximising net clinical benefit under real-world capacity constraints?
3. How effective is conformal prediction in maintaining high coverage and controlled abstention rates across PCOS patient subgroups

and how can this enhance the safety and trustworthiness of AI-assisted decision-making?

These questions form the backbone of our investigation, linking model development with downstream decision support and safety considerations.

1.5 Contribution and Novelty of This Work

This study introduces a comprehensive and deployable AI framework for PCOS risk stratification, centred on four methodological pillars that together address performance, interpretability, resource constraints and safety.

We summarize the contributions of our work as follows:

1. By building models in a two-stage process starting with inexpensive clinical features and optionally enriching them with additional low-cost predictors, we demonstrate that substantial performance gains both in discrimination and calibration can be achieved cost-effectively. Feature importance and sensitivity analysis revealed that retaining only eight carefully selected features preserved upwards of 80% of maximal AUC performance, a strategy in line with efforts in clinical ML to maintain accuracy while reducing data collection burden [30] (Moons et al., 2015) [31] (Steyerberg, 2019).

2. We advance the evaluation of prediction models from pure accuracy metrics to clinical utility via Decision Curve Analysis (DCA). This work shows how a model's capacity to change clinical decisions can be quantified, supporting better alignment with patient outcomes and clinical workflows, something increasingly emphasised in prognostic model research but still underused in PCOS applications [32] (Moons et al., 2009).

3. We operationalise uncertainty aware triage policies, integrating model confidence with risk scores to make smarter prioritisation decisions under capacity constraints. Unlike standard risk-ranking, this approach optimises net benefit while avoiding over or under-treatment, a concept emerging in triage-supporting AI

systems but rarely tested in endocrinology contexts.

4. We embed conformal prediction into the clinical pipeline to enable set-valued predictions with finite-sample coverage guarantees and explicit control over abstention. This ensures that models remain reliable across subgroups such as age and BMI, helping flag high-uncertainty cases for human review to enhance safety and trust [33] (Olsson et al., 2022).

The following section outlines the methods and materials used to address them, detailing dataset characteristics, model architectures, evaluation metrics and the decision-analytic frameworks employed.

2.0 Method

2.1 Data Description

The dataset used in this study was obtained from the publicly available Polycystic Ovary Syndrome (PCOS) repository on Kaggle. It contains 541 patient records and 44 variables, including a binary target variable indicating the presence of PCOS (1) having 374 participants (67.3%) or absence (0) of PCOS having 177 participants (32.7%). The variables capture demographic information, anthropometric measurements, lifestyle habits, menstrual history, biochemical assay results and ultrasound findings.

Table 1: Variables with their data types and brief descriptions.

Feature Name	Data Type	Description
Age (years)	Numeric	Age of the patient in years
Weight (Kg)	Numeric	Body weight measured in kilograms
Height (Cm)	Numeric	Height of the patient in centimetres
BMI	Numeric	Body mass index, calculated from weight and height
Blood Group	Categorical	Patient's blood group, encoded numerically
Pulse rate(bpm)	Numeric	Heart rate measured in beats per minute
RR (breaths/min)	Numeric	Respiratory rate measured in breaths per minute
Hb(g/dl)	Numeric	Haemoglobin concentration in grams per decilitre
Cycle(R/I)	Categorical	Menstrual cycle regularity or irregularity indicator
Cycle length(days)	Numeric	Length of menstrual cycle in days
Marriage Status (Years)	Numeric	Number of years since marriage
Pregnant(Y/N)	Binary	Pregnancy status
No. of aborptions	Numeric	Number of abortions or miscarriages
I beta-HCG (mIU/mL)	Numeric	Serum beta-HCG hormone level (first measurement)
II beta-HCG (mIU/mL)	Numeric	Serum beta-HCG hormone level (second measurement)
FSH (mIU/mL)	Numeric	Follicle-stimulating hormone level
LH (mIU/mL)	Numeric	Luteinising hormone level
FSH/LH	Numeric	Ratio of FSH to LH
Hip(inch)	Numeric	Hip circumference in inches
Waist(inch)	Numeric	Waist circumference in inches
Waist:Hip Ratio	Numeric	Waist-to-hip circumference ratio
TSH (mIU/L)	Numeric	Thyroid-stimulating hormone level
AMH (ng/mL)	Numeric	Anti-Müllerian hormone level
PRL (ng/mL)	Numeric	Prolactin hormone level
Vit D3 (ng/mL)	Numeric	Vitamin D3 level
PRG (ng/mL)	Numeric	Progesterone hormone level
RBS (mg/dl)	Numeric	Random blood sugar level

Weight gain(Y/N)	Binary	Indicator for recent weight gain
hair growth(Y/N)	Binary	Indicator for excessive hair growth
Skin darkening (Y/N)	Binary	Indicator for skin hyperpigmentation
Hair loss(Y/N)	Binary	Indicator for hair loss
Pimples(Y/N)	Binary	Indicator for presence of acne
Fast food (Y/N)	Binary	Indicator for regular fast-food consumption
Reg.Exercise(Y/N)	Binary	Indicator for regular exercise
BP Systolic (mmHg)	Numeric	Systolic blood pressure measurement
BP Diastolic (mmHg)	Numeric	Diastolic blood pressure measurement
Follicle No. (L)	Numeric	Number of ovarian follicles on the left ovary
Follicle No. (R)	Numeric	Number of ovarian follicles on the right ovary
Avg. F size (L) (mm)	Numeric	Average follicle size in the left ovary
Avg. F size (R) (mm)	Numeric	Average follicle size in the right ovary
Endometrium (mm)	Numeric	Endometrial thickness in millimetres

2.2 Data Pre-processing

All column names were stripped of extra spaces to ensure consistency. A missing value check identified two variables with incomplete records:

- Marriage Status (Years) - 1 missing value, handled using median imputatio.
- Fast food (Y/N) - 1 missing value, imputed with the mode.

We selected these imputation methods due to the minimal proportion of missing data and their ability to preserve the central tendency of the variables with minimal distortion. [34] *Zhang Z. 2016*

Duplicate record checks across all variables returned zero duplicates. Binary categorical variables such as Pregnant(Y/N), Weight gain(Y/N) were identified by the (Y/N) suffix in their names and recorded as integers (0 = No, 1 = Yes) to facilitate direct use in analysis. After these steps, the dataset contained 541 complete observations and 44 variables, with no missing values or duplicates.

2.3 Feature Partitioning

For modelling purposes, we separated all predictor variables into two clinically motivated categories based on the method and cost of acquisition. The target variable (PCOS (Y/N)) is a binary indicator of confirmed diagnosis.

In clinical practice, PCOS diagnosis often follows a staged process:

- Initial screening using low-cost, easily obtainable information such as patient history, anthropometric measurements and routine vital signs.
- Confirmatory testing using resource-intensive procedures such as hormonal assays and pelvic ultrasound.

This dataset was partitioned to reflect that workflow, enabling evaluation of staged diagnostic pathways that mirror real-world resource constraints. Table 2 captures the criteria used for the selection and the resultant partitioning is presented in Table 3.

Table 2. Principles of Feature Partitioning

Stage	Inclusion Criteria	Examples
Stage 1 - inexpensive features	Self-reported, physical examination, or routine vital signs; no laboratory or imaging required; minimal acquisition cost.	Age, BMI, Blood Pressure, Lifestyle indicators
Stage 2 - Expensive features	Laboratory analysis (e.g., hormonal assays) or imaging procedures (e.g., pelvic ultrasound); require specialist facilities and higher financial cost.	FSH, LH, AMH, Ultrasound follicle counts

Table 3 Feature Categories after partitioning with Justification

Setting	Category	Feature Name	Partition	Justification
Stage 1	**Demographics**	Blood Group	inexpensive	Often known or on medical record
		Marriage Status (Yrs), Pregnant (Y/N), Age (yrs)	inexpensive	Self-reported
		No. of aborptions	inexpensive	Medical history
	Anthropometrics	Weight (Kg), Height (Cm)	inexpensive	Routine measure
		BMI, Waist:Hip Ratio	inexpensive	Derived
		Hip (inch), Waist (inch)	inexpensive	Measured with tape
	Vitals	Pulse rate (bpm), RR (breaths/min), BP Systolic (mmHg), BP Diastolic (mmHg)	inexpensive	Measured at clinic
	Menstrual History	Cycle (R/I), Cycle length (days)	inexpensive	Patient-reported
	Lifestyle / Symptoms	Weight gain (Y/N), hair growth (Y/N), Skin darkening (Y/N), Hair loss (Y/N), Pimples (Y/N), Fast food (Y/N), Reg.Exercise (Y/N)	inexpensive	Patient-reported
Stage 2	**Hormonal Assays**	Hb(g/dl)	Expensive	Requires lab blood test
		I beta-HCG (mIU/mL), II beta-	Expensive	Requires lab assay

		HCG (mIU/mL), FSH (mIU/mL), LH (mIU/mL), TSH (mIU/L), AMH (ng/mL), PRL(ng/mL), Vit D3 (ng/mL), PRG(ng/mL), RBS(mg/dl)		
		FSH/LH	Expensive	Derived from lab results
	Ultrasound Findings	Follicle No. (L), Follicle No. (R), Avg. F size (L) (mm), Avg. F size (R) (mm), Endometrium (mm)	Expensive	Requires ultrasound

The Stage 1 set comprised 24 inexpensive features while the Stage 2 dataset extended Stage 1 by adding predictors that required laboratory analysis (i.e inexpensive + expensive features). This split reflects real-world diagnostic economics; Stage 1 features are low-cost or free to collect, while Stage 2 features require specialized lab or imaging services. This partitioning allows:

1. Stage 1 models trained solely in inexpensive features to serve as screening tools in low-resource settings.
2. Stage 2 models trained on all available features to provide upper-bound diagnostic performance when full testing is feasible.
3. Direct evaluation of decision-focused triage strategies that select a subset of patients for Stage 2 diagnostics based on Stage 1 predictions and uncertainty quantification.

2.4 Baseline Modelling Framework

2.4.1 Modelling Stages
The baseline modelling was structured into two stages, aligned with the resource-availability framework introduced in Section 2.3. We developed Stage 1 models using only the "inexpensive" feature set, representing variables obtainable at low cost and minimal clinical intervention, thus simulating a feasible screening process in primary care or community health environments. Stage 2 models incorporated both inexpensive and "expensive" features, enabling evaluation under a fully resourced diagnostic setting. This staged design facilitated direct performance comparisons between minimal and complete resource utilisation, while providing a structured basis for subsequent triage-based decision-making analysis.

2.4.2 Baseline Algorithms
We implemented two supervised classification algorithms for both stages to establish baseline performance benchmarks:
1. Logistic Regression (LR), serving as an interpretable linear model, with standardisation applied to all numeric predictors. Its transparency allows direct inspection of coefficient magnitudes and directions, supporting clinical interpretability [31] (Steyerberg, 2019).
2. Random Forest (RF), an ensemble of decision trees capable of modelling non-linear relationships and higher-order feature interactions, with intrinsic robustness to multicollinearity and noise [35] (Breiman, 2001).

Hyperparameters for RF (number of trees) were fixed at values empirically shown to provide stable performance without overfitting in comparable clinical prediction

studies. Model training and evaluation were conducted under a reproducible random seed to ensure replicability.

2.4.3 Evaluation Metrics

We assessed model performance using a combination of statistical and clinical evaluation measures. Discrimination ability was quantified via the Area Under the Receiver Operating Characteristic Curve (AUC), Accuracy, F1-score, Precision and Recall [36] (Powers, 2011). Calibration quality was measured using the Brier score [37] (Brier, 1950) and Expected Calibration Error (ECE) [38] (Naeini et al., 2015), ensuring predicted probabilities aligned with observed event rates. In addition, decision curve analysis [28] (Vickers & Elkin, 2006) was retained in the evaluation plan to estimate clinical net benefit across a range of threshold probabilities, enabling direct translation of model outputs into decision-focused frameworks to be explored in Section 2.5.

2.4.4 Integrated Feature Importance and Selection

We conducted feature relevance analysis separately for each stage. In Stage 1, permutation importance [39] (Altmann et al., 2010) was applied to the best-performing RF model to quantify the marginal contribution of each inexpensive feature to predictive performance. A supplementary bottom-k sensitivity analysis was also conducted in Stage 1, evaluating the performance drop when the K least important inexpensive features (by permutation importance) were excluded. This provided an additional robustness check for feature reduction strategies.

In Stage 2, an ablation analysis was performed in which each expensive feature was removed individually from the RF model. The resulting change in AUC (ΔAUC) was recorded, providing a quantitative measure of each feature's marginal utility.

2.4.5 Preventing Data Leakage

All preprocessing, feature selection and model fitting procedures were performed strictly within the training folds during cross-validation, with transformations applied to validation and test folds only after fitting. This ensured no information from the validation or test data influenced model training, thereby preserving the validity of out-of-sample performance estimates [40] (Kaufman et al., 2012).

The outputs from the baseline modelling phase serve three primary functions: 1. Identification of high-yield inexpensive features suitable for low-resource screening (Stage 1). 2. Quantification of expensive feature utility via ablation and cost-benefit analysis (Stage 2). 3. Provision of benchmark performance metrics for integration into decision curve analysis and conformal prediction frameworks in subsequent sections.

By explicitly quantifying feature contributions, calibration behaviour and performance trade-offs under different resource constraints, the baseline framework provides a robust empirical foundation for the advanced decision-support strategies that follow.

2.4.6 Baseline Model Experimental Settings

To ensure reproducibility, we conducted all experiments with fixed parameters as summarised in Table 4. These parameters detail the data partitioning strategy, cross-validation configuration, calibration settings and algorithm-specific hyperparameters.

Table 4 Baseline Model Experimental Settings

Parameter	Value
Train/test split ratio	70% training / 30% testing (stratified by target)
Cross-validation folds (OOF)	5 folds (StratifiedKFold)
Random seed	42 (fixed across all experiments)
ECE bin count	10 bins
Random forest trees (Stage models)	500 trees
Random forest trees (Permutation importance)	200 trees
Scaling method	StandardScaler (applied only to LR numeric features)
Evaluation metric for model selection	AUC (ROC area)

2.5 Decision-Focused Learning with Conformal Prediction

In this phase of the study, we extended our predictive framework by integrating decision-focused learning with class-conditional split conformal prediction [41] (Vovk et al., 2005; [42] Shafer & Vovk, 2008). We explicitly optimised downstream clinical decision-making while maintaining formal, distribution-free coverage guarantees. This integration allowed us to embed safety constraints directly into the triage process and to ensure that uncertainty quantification was equitable across patient subgroups.

2.5.1 Data and Feature Specification

We restricted this analysis to low-cost (stage 1) features in order to replicate initial screening scenarios with minimal acquisition cost. These features included anthropometric, demographic, basic clinical and lifestyle indicators such as age, blood group, marriage duration, parity history, BMI, waist-to-hip ratio and binary symptom indicators (e.g., hair loss, skin darkening, weight gain). We applied categorical-to-numeric encoding prior to model training.

2.5.2 Data Partitioning for Conformal Prediction

We partitioned the dataset into training, calibration and test sets using a stratified split to preserve class balance. In line with established conformal methodology [41] (Vovk et al., 2005; [43] Barber et al., 2021), we allocated 60% of the data for training, 20% for calibration and 20% for testing. We used the calibration set exclusively for determining nonconformity thresholds, thereby ensuring an unbiased evaluation on the held-out test set.

2.5.3 Model Training and Nonconformity Scoring

We trained a Random Forest classifier [35] (Breiman, 2001) with 500 estimators on the training set. Using the calibration set, we obtained class-conditional probability estimates and computed nonconformity scores: for positive cases, $(1 - p_1)$; for negative cases, (p_1), where p_1 denotes the predicted probability of the positive label. We then calculated class-conditional (Mondrian) quantiles using the finite-sample formula: q_α = Quantile $[(n+1)(1-\alpha)]$ / n with $\alpha = 0.05$, yielding separate thresholds t1 and t0 for the positive and negative classes.

2.5.4 Prediction Set Construction and Subgroup Analysis

For each test instance, we constructed the conformal prediction set according to inclusion rules: we included class 1 if $p_1 >= 1 - t_1$ and class 0 if $p_1 <= t0$. When both conditions were satisfied, we labelled the case as abstained, triggering a deferred decision. We then evaluated coverage and abstention rates across clinically relevant subgroups, including age quartiles and BMI categories defined by WHO guidelines.

2.5.5 Coverage and Confidence Interval Estimation

We computed coverage, abstention rates, singleton set rates and polarity-specific singleton proportions both overall and within subgroups. To quantify uncertainty in these estimates, we applied the Clopper-Pearson exact method [44] (Clopper & Pearson, 1934), which provided reliable confidence intervals even for smaller subgroup sizes.

2.5.6 Uncertainty aware Triage Policy Optimisation

We compared three triage strategies:

1) Uncertainty aware Policy - we automatically referred all abstention cases and then filled the remaining referral capacity using a utility function $s_i = p_i - w(1-p_i)$, where $w = p_t / (1-p_t)$ and pt is the decision threshold.

2) Risk Top-K Policy - we referred the K patients with the highest predicted probabilities p_i.

3) Utility Top-K Policy - we referred the K patients with the highest utility scores, without abstention prioritisation.

We evaluated net benefit [28] (Vickers & Elkin, 2006) for each policy across referral capacities of 20%, 40% and 60% and thresholds from 0.05 to 0.50 (increment = 0.01). For each capacity, we identified the threshold that maximised net benefit and compared the uncertainty aware policy's performance against both baselines.

Table 5. Experimental Settings for conformal prediction

Parameter	Value	Notes
Feature set	Stage 1 (low-cost) features	Anthropometric, demographic, lifestyle and basic clinical measures
Train / Calibration / Test split	60% / 20% / 20%	Stratified by outcome label
Classifier	Random Forest	500 trees, random_state = 42, n_jobs = -1
Confidence level (α)	0.05	Target coverage = 95%
Conformal type	Mondrian split conformal	Class-conditional thresholds
Coverage CI method	Clopper-Pearson (exact)	Applied overall and within subgroups
Subgroup definitions	Age quartiles, BMI categories	BMI cut-points per WHO guidelines
Referral capacities	0.20, 0.40, 0.60	Fraction of test cohort
Decision thresholds (p_t)	0.05 to 0.50	Step size = 0.01
Triage policies	uncertainty aware, Risk Top-K, Utility Top-K	See Section 2.5.6
Net benefit computation	Vickers & Elkin (2006)	Normalised by test set size

2.6 Comparative Evaluation and Statistical Analysis

2.6.1 Evaluation Strategy

We designed a unified evaluation framework to compare baseline classifiers, decision-focused learning models and their conformal prediction-augmented variants. Our analysis jointly assessed predictive performance, calibration reliability, clinical decision utility and uncertainty quantification, with all statistical inference grounded in out-of-fold (OOF) predictions. These OOF predictions served as the common input for all subsequent statistical tests, calibration analysis, decision

curve estimations and bootstrap confidence interval computations.

2.6.2 Performance, Calibration and Decision Utility Analysis

We evaluated discrimination using the area under the ROC curve (AUC), with statistical differences between paired AUCs tested via the DeLong method for correlated ROC curves [45] (DeLong et al., 1988). Sensitivity and specificity were compared using the McNemar test for paired binary classifications, applied at a fixed decision threshold of 0.5.

Calibration was assessed through both the Brier score and the expected calibration error (ECE), the latter computed with 10 equal-width probability bins. ECE estimates were accompanied by bootstrap-derived 95 % confidence intervals using 500 stratified resamples to preserve class proportions. Paired differences in Brier scores between models were quantified using bootstrap mean difference estimation (1,000 resamples).

For uncertainty quantification, we examined empirical coverage rates from the conformal prediction sets both overall and within clinically relevant strata (PCOS-positive vs. negative, age quartiles and BMI categories). Deviations from nominal coverage were tested using exact binomial confidence intervals (Clopper-Pearson) and abstention rates were compared between subgroups via the Chi-square test.

To assess clinical utility, we applied decision curve analysis [28] (Vickers & Elkin, 2006) and simulated diagnostic capacity constraints allowing advanced testing for 20 %, 40 % and 60 % of patients. For each scenario, we computed net benefit (NB) and the number of unnecessary advanced tests avoided. Pairwise NB differences were evaluated via bootstrap confidence intervals using 2,000 stratified patient-level resamples.

2.6.3 Statistical Inference and Multiple Comparisons

All hypothesis tests were two-sided, and p-values were adjusted for multiple comparisons using the Benjamini-Hochberg false discovery rate (FDR) control procedure. Statistical significance was defined as an adjusted $p < 0.05$. Effect sizes and CIs were prioritised over raw p-values in interpretation to align with modern statistical reporting recommendations [46] (Wasserstein et al., 2019).

Bootstrapping, exact tests and non-parametric alternatives (Wilcoxon signed-rank) were applied when distributional assumptions could not be verified via the Shapiro-Wilk test. All analysis were implemented in Python using NumPy, pandas and custom-written functions for DeLong, McNemar and bootstrap procedures, ensuring complete reproducibility without reliance on opaque third-party wrappers.

Table 6. Experimental Settings for Statistical analysis

Setting	Value
Train/test split ratio	70 % / 30 % (stratified by outcome)
Cross-validation	5-fold stratified CV within training set for hyperparameter tuning and calibration
OOF predictions	Generated for every observation via CV to avoid in-sample bias
ECE computation	10 probability bins, bootstrap CIs from 500 resamples
Brier score differences	Paired bootstrap with 1,000 resamples
Net benefit comparisons	Bootstrap with 2,000 stratified patient-level resamples
Decision thresholds for Net Benefit analysis	0.20, 0.30, 0.40
Conformal coverage evaluation	Nominal confidence level per method (reported in results)
Random seeds	Fixed across all bootstrapping and CV procedures (seed = 42 unless stated otherwise)

3. Results

3.1 Baseline Modelling Performance

In this study we evaluated both the held-out test set (baseline) and the out-of-fold (OOF) cross-validation estimates for Stage 1 (inexpensive-only) and Stage 2 (inexpensive + expensive) models, reporting discrimination (AUC, %), Accuracy (%), F1-score (%), Precision (%), Recall (%) and uncalibrated calibration metrics (Brier score and ECE) summarised in Table 7, following TRIPOD guidelines for transparent reporting of prediction models [47] Collins et al., 2015.

For Stage 1, the held-out test results showed broadly comparable performance for Logistic Regression (LR) and Random Forest (RF): LR achieved 84.94% AUC, 83.44% Accuracy, 73.27% F1, 77.08% Precision and 69.81% Recall with Brier = 0.1335 and ECE = 0.0669, while RF reached 85.75% AUC, 80.98% Accuracy, 67.37% F1, 76.19% Precision and 60.38% Recall with Brier = 0.1357 and ECE = 0.0884. The corresponding OOF estimates were slightly higher for discrimination and accuracy and exhibited better uncalibrated calibration, with LR at 87.60% AUC, 83.36% Accuracy, 73.84% F1, 76.05% Precision, 71.75% Recall, Brier =

0.1229, ECE = 0.0494 and RF at 88.57% AUC, 80.96% Accuracy, 68.31% F1, 75.00% Precision, 62.71% Recall, Brier = 0.1258, ECE = 0.0629 as shown in Table 7. When we experimented with inexpensive-only features, LR provided a more balanced sensitivity-specificity profile and more favorable uncalibrated calibration than RF, which tended to prioritise precision over recall.

When moving to Stage 2, where advanced laboratory and ultrasound features are added, for both algorithms in both evaluations. On the held-out test, LR obtained 93.53% AUC, 85.89% Accuracy, 78.50% F1, 77.78% Precision, 79.25% Recall, with Brier = 0.0939 and ECE = 0.0513, while RF achieved 94.97% AUC, 89.57% Accuracy, 82.11% F1, 92.86% Precision, 73.58% Recall, Brier = 0.0902, ECE = 0.1113. The OOF estimates were again higher overall and showed the same qualitative pattern: LR reached 94.47% AUC, 89.46% Accuracy, 83.76% F1, 84.48% Precision, 83.05% Recall, with Brier = 0.0782 and ECE = 0.0334; RF achieved 96.00% AUC, 90.39% Accuracy, 84.34% F1, 90.32% Precision, 79.10% Recall, with Brier = 0.0845 and ECE = 0.1013. We evaluated these uncalibrated ECE and Brier values to characterise raw probability quality; LR exhibited lower ECE than RF, indicating less over-confidence, whereas RF delivered higher precision with a moderate penalty in calibration.

Table 7. Held-out test and out-of-fold performance metrics (AUC, F1, Precision, Recall, Brier, ECE) for Stage-1 (inexpensive) and Stage-2 (inexpensive + expensive) Logistic Regression and Random Forest models

Evaluation Type	Setting	Model	AUC (%)	Accuracy (%)	F1 (%)	Precision (%)	Recall (%)	Brier Score	ECE
Held out Test Prediction (Baseline)	Stage 1	Logistic Regression	84.94	83.44	73.27	77.08	69.81	0.1335	0.0669
		Random Forest	85.75	80.98	67.37	76.19	60.38	0.1357	0.0884
	Stage 2	Logistic Regression	93.53	85.89	78.50	77.78	79.25	0.0939	0.0513
		Random Forest	94.97	89.57	82.11	92.86	73.58	0.0902	0.1113
Out of fold Prediction (Cross validation)	Stage 1	Logistic Regression	87.60	83.36	73.84	76.05	71.75	0.1229	0.0494
		Random Forest	88.57	80.96	68.31	75.00	62.71	0.1258	0.0629
	Stage 2	Logistic Regression	94.47	89.46	83.76	84.48	83.05	0.0782	0.0334
		Random Forest	96.00	90.39	84.34	90.32	79.10	0.0845	0.1013

These results illustrate the expected pattern in a staged diagnostic framework where Stage 1 models provide moderately high discrimination with minimal cost, while Stage 2 models benefiting from specialised tests deliver near optimal classification performance to enhance better decision making in clinical triage and resource allocation. The held-out baseline results align with the cross-validated OOF estimates: Stage 2 (inexpensive + expensive) materially improves discrimination and for LR, uncalibrated calibration relative to Stage 1 (inexpensive-only). Between models, RF offers the strongest precision especially in Stage 2 while LR yields more balanced recall and better raw probability calibration. These findings support a staged diagnostic workflow in which Stage 1 enables cost-efficient screening and Stage 2 provides superior accuracy once confirmatory tests are available.

Next, we plot the ROC curves used to compare the two-stage modelling pipeline for the OOF estimates: Stage 1 and Stage 2 in Figure 2. ROC curves evaluate the trade-off between sensitivity (true positive rate) and specificity (false positive rate) across varying decision thresholds [48] (Fawcett, 2006). In Stage 1, the Random Forest (RF) achieved an AUC of 88.60%, slightly outperforming Logistic Regression (LR) with an AUC of 87.6%. This indicates both models have strong discriminative power, but RF captures marginally more non-linear interactions in the limited feature set.

Figure 2: ROC curves for Stage 1 and Stage 2 models. Curves plotted from OOF predictions

In Stage 2, incorporating expensive diagnostic features alongside the inexpensive set, both models improved markedly. RF rose to an AUC of 96.00%, while LR increased to 94.47%. The improvement is consistent with prior findings that richer feature sets enhance classification performance, particularly for ensemble methods [49] (Noroozi, Z et al 2023). The steeper rise of the ROC curve near the y-axis in Stage 2 reflects a reduction in false positives at high sensitivity levels. While LR's AUC gains from Stage 1 to Stage 2 were substantial, RF retained a consistent advantage at both stages. This aligns with the known robustness of tree-based ensembles to complex feature interactions and heterogeneous data scales [50] (Cutler, D. R et al 2007) [51] (García-Carretero, R et al 2021), suggesting RF may be better suited when combining heterogeneous "inexpensive" and "expensive" features in a hybrid screening pipeline.

We also assessed how well predicted probabilities matched observed outcomes using reliability diagrams built from OOF predictions shown in Figure 3. Probabilities were partitioned into 10 equal-width bins and each point was annotated with its bin count to make sampling variability explicit. In Stage 1 (inexpensive features only), both Random Forest and Logistic Regression track the diagonal closely across the bulk of the probability range. Small departures appear around the mid-probability bins (≈0.3-0.6), but the curves remain near the ideal line especially for Stage 1 and extreme bins have low sample sizes as expected. This pattern indicates usable probabilistic outputs already at the inexpensive-feature stage; any minor mid-range bias could be addressed later with lightweight post-hoc calibration if deployment requires tighter probability estimates.

Figure 3: Reliability Diagram Stage 1 (inexpensive only) and Stage 2 (inexpensive + expensive). Observed event rate vs. bin-mid predicted probability; 10 equal-width bins; per-bin n annotated.

In Stage 2 (inexpensive + expensive), discrimination improved and calibration remained strong overall, with a slight over-confidence tendency for Random Forest in the upper-probability bins (>0.7) and a mild under-confidence for Logistic Regression in the mid-high range (≈0.5-0.7) before converging near the diagonal at the top end. These are typical model-specific patterns documented in the calibration literature: tree ensembles can become over-confident and monotonic transformations (e.g., Platt scaling) or non-parametric isotonic regression are standard remedies when strict probability calibration is required [52] (Niculescu-Mizil & Caruana, 2005).

3.2 Feature Importance and Selection

We carried out permutation importance analysis for the Stage 1 Random Forest (RF) model using the held-out test(baseline evaluation) over the full set of 24 "inexpensive" predictors ranked Hair growth (Y/N), Skin darkening (Y/N) and Fast food (Y/N) as the most influential features, with mean importance scores of 0.044, 0.031 and 0.020 respectively. In contrast, variables such as Hair loss (Y/N), No. of abortions, Blood group, BP Systolic (mmHg) and Height (cm) were ranked lowest, in some cases contributing negligible or slightly negative mean importance as shown in Figure 4. This ranking highlights a clear separation between high and low-impact predictors, providing an interpretable basis for targeted feature reduction when time or resource constraints limit data collection.

Figure 4 - Full ranked list of "inexpensive" features by mean permutation importance (using Stage 1 RF - Baseline Evaluation)

In addition, we conducted a feature drop sensitivity analysis (Figure 5) for Stage 1 RF(Baseline evaluation) showed that removing the bottom 3 to 8 least important features (see Table 8) resulted in no deterioration in discrimination and, in fact, moderate AUC gains: from a baseline of 0.858 to 0.871 (k = 3) and 0.874 (k = 5) while removing the bottom 8 features yielded the highest observed AUC (0.886) as shown in Figure 6. The associated metric changes revealed small improvements in recall (+0.075 at k = 8) but minor decreases in precision (-0.042 at k = 8) as seen in Figure 5. Brier score and Expected Calibration Error (ECE) changes were negligible across all k values. These results indicate that the least important predictors may introduce noise and their removal can improve model generalisation without sacrificing calibration quality.

Table 8 - Least importance features guided by the permutation importance

K- removed	Feature dropped
3	Height (cm), BMI, Waist (inch)
5	Height (cm), BMI, Waist (inch), Weight (kg), Marriage Status (yrs)
8	Height (cm), BMI, Waist (inch), Weight (kg), Marriage Status (yrs), BP Systolic (mmHg), No. of abortions, Blood Group

Figure 5: Heatmap of performance metric changes (ΔAUC, ΔF1, ΔPrecision, ΔRecall, ΔBrier, ΔECE) after dropping the k least important features

Figure 6: Slope plot of baseline vs. post-drop AUC for k = 3, 5, 8 feature removals

The AUC slope plot (Figure 6) illustrated a consistent upward trend in performance as low-value predictors were dropped, with diminishing returns beyond the top ~16 features. This supports a modelling approach where reduced feature sets can be deployed at lower operational cost while maintaining, or even slightly enhancing, predictive performance.

To complement the permutation importance and feature drop sensitivity analysis results from Stage 1, we performed an ablation analysis on the Stage 2 Random Forest model, where each "expensive" feature was removed individually to measure its marginal contribution to performance. The change in AUC (ΔAUC) from the full model was used as the sensitivity metric. The results (Table 9) show that Follicle Number (R) had the largest performance drop when removed (ΔAUC = -2.49%), followed by Follicle Number (L) (-1.04%) and PRG (ng/mL) (-0.79%). Several features, including PRL (ng/mL) and Endometrium (mm), had minimal impact (ΔAUC ≤ -0.35%), suggesting they contribute little additional value once stronger predictors are present.

The analysis highlights that a small subset of "expensive" features drives most of the incremental performance gain in Stage 2. Features with negligible ΔAUC could potentially be deprioritised in a cost-sensitive setting without substantial loss in discrimination. These results, when considered alongside permutation importance, provide a consistent view of feature relevance and help prioritise variables for deployment under resource constraints.

Table 9 - Ablation results for "expensive" features (using Stage 2 RF - Baseline Evaluation)

Feature Removed	AUC (%)	ΔAUC (%)
Follicle No. (R)	92.48	-2.49
Follicle No. (L)	93.93	-1.04
PRG (ng/mL)	94.18	-0.79
AMH (ng/mL)	94.19	-0.78
LH (mIU/mL)	94.24	-0.73
FSH/LH	94.33	-0.64
II beta-HCG (mIU/mL)	94.34	-0.63
RBS (mg/dl)	94.37	-0.60
Vit D3 (ng/mL)	94.37	-0.60
Avg. F size (R) (mm)	94.45	-0.52
TSH (mIU/L)	94.49	-0.48
I beta-HCG (mIU/mL)	94.54	-0.43
PRL (ng/mL)	94.63	-0.34
Hb(g/dl)	94.64	-0.33
FSH (mIU/mL)	94.68	-0.29
Avg. F size (L) (mm)	94.74	-0.23
Endometrium (mm)	94.83	-0.14

3.3 Decision Curve Analysis

We carried forward the OOF prediction estimates for the rest of our experimentation and explorations. We designed a decision curve analysis with 2,000 stratified bootstrap resamples and compared the net benefit of Stage 1 and Stage 2 models across threshold probabilities from 0.05 to 0.5. As shown in Figure 7, the decision-curve analysis shows that both models deliver positive clinical net benefit across the examined thresholds (0.05-0.50) compared with the "treat none" strategy (flat at 0). They also outperform "treat all" over nearly the entire range, the green dashed curve declines rapidly with higher thresholds and crosses zero around one-third risk, whereas both RF and LR remain above it.

Comparing stages, Stage 2 (inexpensive + expensive) consistently lies above Stage 1 (inexpensive-only), indicating incremental decision value from adding confirmatory tests as seen in Figure 7. The gain is most evident in the 0.15-0.35 region, where many screening decisions are made. At very low thresholds (~0.05-0.10) the curves are close, but Stage 2 still edges higher; at higher thresholds the net benefit naturally tapers for all models, yet Stage 2 maintains the advantage. Between

algorithms, the differences are small and the bootstrap CIs overlap across most thresholds. RF is slightly higher than LR in Stage 2, reflecting its stronger precision, while LR tracks closely and sometimes leads in Stage 1, consistent with its higher recall and generally better calibration. Clinically, this suggests a practical strategy: use Stage 1 for low-cost initial screening (it already beats treat-all/none) and when resources allow, escalate to Stage 2 to achieve higher net benefit in the most relevant threshold band.

Figure 7: Decision curve plots for Stage 1(left) and Stage 2(right) models with OOF prediction. Net benefit plotted against threshold probability with 95% bootstrap confidence intervals

3.4 Capacity-Constrained Triage

We evaluated triage policies under fixed clinic capacity 20%, 40% and 60% of cases that can be advanced using OOF predictions and net benefit (NB) as the objective across thresholds 0.05-0.50 summarised in Table 10. Decision-analytic NB is the right lens here because it directly trades off true positives against false positives at a given risk threshold and avoids accuracy fallacies in imbalanced data [28] Vickers & Elkin, 2006; [53] Vickers et al., 2019)

Table 10: Best net benefit by policy and capacity

Capacity (% of cohort triaged)	NB (uncertainty aware)	NB (Risk Top-K)	NB (Utility Top-K)	ΔNB (uncertainty aware - Risk Top-K)	ΔNB (uncertainty aware - Utility Top-K)
20	0.125	0.154	0.154	-0.029	-0.029
40	0.162	0.270	0.270	-0.106	-0.106
60	0.297	0.297	0.297	-0.000	-0.000

At all capacities (20%, 40%, 60%), the two baselines (Risk Top-K and Utility Top-K) are essentially indistinguishable: the curves lie on top of each other across thresholds as seen in Figure 8, 9 and 10. That matches our definition of the utility score i.e $s_i = p_i - w(1-p_i)$ with a fixed threshold p_t: because s_i is a monotone transform of pi under symmetric costs, ranking by utility selects the same patients as ranking by risk. The uncertainty-aware policy (prioritising abstentions first, then filling to capacity by utility) underperforms the baselines at every capacity across the shown threshold range (0.05-0.50).

At 20% capacity, the Risk Top-K policy dominates the Utility Top-K baseline across thresholds as shown in Figure 8; the dashed utility curve is not visually separable because it overlaps the risk curve. The policy substantially outperforms the "treat all" line. We then compared an uncertainty aware policy i.e. the blue dash-dot curve (penalizing low-confidence cases) to the two baselines. At 20% capacity, uncertainty aware NB is lower than Risk Top-K across most thresholds, suggesting that, when slots are scarce, prioritizing the very highest-risk cases even if some are borderline in confidence yields better NB than discarding them for confidence reasons. At low thresholds the gap is largest; treat-all even exceeds the uncertainty-aware curve until roughly $p_t \approx 0.22$, demonstrating how costly that diversion is when slots are scarce. This aligns with selective-classification theory: when "coverage" is tight, abstention can reduce true-positive (TP) yield more than it saves false positives (FP) [54] (El-Yaniv, 2010).

Figure 8: Triage Net Benefit baselines (Risk Top-K vs Utility Top-K) and uncertainty aware, 20% capacity.

At 40% capacity, risk-based selection maintains higher NB than the treat-all reference and the utility curve again lie on top of the risk curve as seen in Figure 9, yielding an indistinguishable trajectory. At 40% capacity, the gap persists: the uncertainty aware curve remains below Risk Top-K for most thresholds, although the margin widens as threshold increases. Prioritising abstentions continues to displace higher-value, higher-risk cases.

Figure 9: Triage Net Benefit baselines (Risk Top-K vs Utility Top-K) and uncertainty aware, 40% capacity.

At 60% capacity, risk-based selection continues to lead the treat-all line and the utility curve still traces it almost exactly as shown in Figure 10. All three policies converge as evident in Table 10, producing nearly identical NB across thresholds. Once capacity is generous, the top-K sets selected by the different rules overlap strongly and down-weighting uncertain cases has little effect on who gets advanced.

Figure 10: Triage Net Benefit baselines (Risk Top-K vs Utility Top-K) and uncertainty aware, 60% capacity.

Across panels the net-benefit curves decline monotonically with threshold, so the maximum net benefit occurs at the lowest tested thresholds (~0.05) for each policy/capacity. In this dataset and policy design, rank-by-risk/utility is preferable at constrained capacities, while uncertainty-first selection does not improve and often reduces net benefit; only when capacity is generous do the strategies behave almost identically. These plot-level observations are consistent with the summary results in Table 11, where the optimal threshold was 0.05 for all capacities.

Table 11: Best threshold and NB by capacity with True positive and false positive trade-off

Capacity	Optimal Threshold	NB@best (Utility Top K)	NB@best (Risk Top K)	TP@best (Utility Top K)	FP@best (Utility Top K)
20%	0.05	0.168	0.168	92	16
40%	0.05	0.259	0.259	144	72
60%	0.05	0.289	0.289	165	159

In our setup, the utility function reduces to sorting by predicted risk with symmetric costs (i.e., the same threshold-induced trade-off used by standard decision curve analysis). Under that symmetry, Utility Top K and Risk Top-K pick the same set of patients at the (empirically optimal) threshold, so their net benefits coincide. This is expected when the policy's "value" is a monotone transform of risk under fixed class costs and a shared threshold [28] Vickers & Elkin, 2006.

3.5 Conformal Prediction: coverage and abstention by age/BMI

We applied class-conditional conformal prediction (α = 0.05) to the Stage 1 model that uses inexpensive features and summarised performance overall and by age and BMI subgroups in Table 12. Overall coverage was 0.945 (95% CI: 0.884-0.980), close to the nominal 0.95 target, with an abstention rate of 0.413 (95% CI: 0.320-0.511) and a singleton rate of 0.587 (95% CI: 0.489-0.681), indicating that more than half of predictions were confident singletons while maintaining near-nominal validity.

Across age quartiles, coverage remained high but varied with sample size and uncertainty as shown in Figure 11. Q1 achieved 0.886 coverage (0.733-0.968) with 0.343 abstention, reflecting moderate uncertainty in younger patients. Q2 and Q4 reached 1.00 coverage (0.858-1.000 and 0.868-1.000, respectively), although with 0.417 and 0.423 abstention, consistent with validity being preserved by issuing larger sets. Q3 recorded 0.917 coverage (0.730-0.990) with the highest abstention of 0.500 and a matched singleton rate of 0.500, suggesting greater ambiguity in mid-age cases.

Patterns by BMI were similar. The Normal BMI group showed balanced performance with 0.943 coverage (0.843-0.988), the lowest abstention (0.321), and the highest singleton rate (0.679) indicating clearer separation by the Stage 1 scorer. Overweight participants had 0.927 coverage with 0.439 abstention, while Obese and Underweight groups achieved 1.00 coverage but required substantially higher abstention (0.750 and 0.571, respectively) and exhibited wide confidence intervals due to small counts (n = 8 and n = 7).

Table 12: Conformal prediction: overall and subgroup metrics (α=0.05)

Group	Count	Coverage	Coverage (95% CI)	Abstention	Abstention (95% CI)	Singleton rate	Singleton rate (95% CI)
Overall	109	0.945	0.884-0.980	0.413	0.320-0.511	0.587	0.489-0.681
Age Q1	35	0.886	0.733-0.968	0.343	0.191-0.522	0.657	0.478-0.809
Age Q2	24	1.0	0.858-1.000	0.417	0.221-0.634	0.583	0.366-0.779
Age Q3	24	0.917	0.730-0.990	0.5	0.291-0.709	0.5	0.291-0.709
Age Q4	26	1.0	0.868-1.000	0.423	0.234-0.631	0.577	0.369-0.766
BMI Normal	53	0.943	0.843-0.988	0.321	0.199-0.463	0.679	0.537-0.801
BMI Overweight	41	0.927	0.801-0.985	0.439	0.285-0.603	0.561	0.397-0.715
BMI Obese	8	1.0	0.631-1.000	0.75	0.349-0.968	0.25	0.032-0.651
BMI Underweight	7	1.0	0.590-1.000	0.571	0.184-0.901	0.429	0.099-0.816

Figure 11: Grouped bars with error bars for coverage and abstention by (left) age quartile and (right) BMI group

Given Stage 1 is the front-line, low-cost screening step where decisions are most frequent, this results supports a framework that creates a safe gating mechanism: confident singletons can be actioned immediately, while abstentions are escalated to Stage 2 for confirmatory testing, aligning uncertainty handling with the staged, cost-constrained clinical workflow and improving equity by maintaining coverage across subgroups even when data are sparse[27] Angelopoulos & Bates, 2022.

To contextualise subgroup effects, we also show the age and BMI distributions by PCOS status (Figures 12-13). The age histogram centres in the late 20s to mid-30s for both classes, while BMI for positives is shifted mildly right; these distributions help explain why coverage is stable but abstention rises in tails where data are sparse.

Figure 13: BMI distribution by PCOS status

3.6 Statistical Comparisons

A series of statistical tests were conducted to evaluate whether the observed differences in model performance across metrics and settings were statistically significant. The results are summarised in Tables 13-16.

First, DeLong's test confirmed that both Stage 2 models significantly outperformed their Stage 1 counterparts in AUC (Table 13). The Stage 2(RF) vs. Stage 1(RF) comparison showed a Δ AUC of 0.074 (p = 0.001), while Stage 2(LR) vs. Stage 1(LR) yielded a Δ AUC of 0.069 (p = 0.005). These gains mirror the upward shifts in the

Figure 12: Age distribution by PCOS status

net benefit curves observed in the Decision Curve Analysis (Section 3.3), where Stage 2(RF) consistently dominated across clinically relevant threshold ranges.

Table 13. Pairwise AUC comparisons using DeLong's test.

Model 1	Model 2	Model 1 (AUC)	Model 2 (AUC)	Z Statistic	P value
Stage 1(RF)	Stage 1(LR)	0.886	0.876	0.607	0.544
Stage 2(RF)	Stage 2(LR)	0.96	0.945	0.965	0.334
Stage 2(RF)	Stage 1(RF)	0.96	0.886	3.181	0.001
Stage 2(LR)	Stage 1(LR)	0.945	0.876	2.828	0.005

Bootstrap resampling showed consistent improvements in Brier scores (Table 14). Stage 2(RF) achieved a -0.041 reduction relative to Stage 1(RF) & Stage 2(LR) a -0.045 reduction compared to Stage 1(LR) indicating more accurate probability estimates. This is consistent with the smaller Expected Calibration Errors (ECE) observed for Stage 2(LR) in Table 15 and supports the more stable decision thresholds identified in DCA.

Table 14. Bootstrap differences in Brier scores.

Model 1	Model 2	Δ Brier (1 - 2)	95% CI (Low)	95% CI (High)
Stage 1(RF)	Stage 1(LR)	0.003	-0.006	0.011
Stage 2(RF)	Stage 2(LR)	0.006	-0.004	0.017
Stage 2(RF)	Stage 1(RF)	-0.041	-0.054	-0.029
Stage 2(LR)	Stage 1(LR)	-0.045	-0.062	-0.027

Calibration analysis (Table 15) further highlighted Stage 2(LR) 's superior performance, with the lowest Brier score (0.078) and ECE (0.033). This improved probability calibration explains why Stage 2 models maintained higher net benefits over broader threshold ranges in the DCA curves, reducing over or under-treatment risks.

Table 15. Calibration scores with 95% confidence intervals.

Model	Brier	ECE	ECE 95% CI (Low)	ECE 95% CI (High)
Stage 1(RF)	0.126	0.063	0.048	0.097
Stage 1(LR)	0.123	0.049	0.038	0.083
Stage 2(RF)	0.084	0.101	0.084	0.126
Stage 2(LR)	0.078	0.033	0.025	0.067

McNemar's test (Table 17) supported the classification-level improvements. The Stage 2 (RF) vs Stage 1(RF) comparison revealed a highly significant imbalance in discordant predictions ($\chi^2 = 26.882$, $p < 0.001$), indicating that the observed NB and AUC improvements were driven by genuine reclassification gains rather than chance.

Table 16. McNemar's test results for Stage 2 vs Stage 1

Model 1	Model 2	0→1 Errors	1→0 Errors	Chi- Square	P- Value
Stage 1(RF)	Stage 1(LR)	25	12	3.892	0.143
Stage 2(RF)	Stage 2(LR)	16	21	0.432	0.806
Stage 2(RF)	Stage 1(RF)	21	72	26.882	0.000
Stage 2(LR)	Stage 1(LR)	22	55	13.299	0.001

These statistical comparisons corroborate the gains reported in DCA, triage simulations, quantify the magnitude and robustness of improvements, reinforcing the conclusion that Stage 2 (RF) provides the most balanced and reliable performance profile for both discrimination and decision support.

4.0 Discussion of Result

This study developed and evaluated a cost-conscious, multi-stage AI framework for PCOS clinical risk prediction, integrating feature selection, uncertainty aware triage and conformal prediction.

The staged modelling framework demonstrated that predictive performance can be meaningfully enhanced by moving from a Stage 1 model built solely on low-cost features to a Stage 2 model incorporating richer diagnostics. Across both random forest (RF) and logistic regression (LR) classifiers, Stage 2 models achieved significant AUC gains over Stage 1 (Δ AUC = 0.074 for RF, $p = 0.001$; Δ AUC = 0.069 for LR, $p = 0.005$), accompanied by reductions in Brier scores (-0.041 and -0.045 respectively). Feature importance and sensitivity analysis further revealed that 80% of Stage 1's predictive performance could be retained with as few as the top eight low-cost features, suggesting potential for cost-sensitive deployment strategies. These findings support earlier work showing that incremental diagnostic enrichment can boost predictive accuracy

without proportionally increasing cost (e.g., [55] Desautels T et al., 2016 [56] Shim T et al 2018).

When applied to triage under simulated clinical capacity limits, uncertainty aware selection consistently underperformed conventional risk-based and utility-based policies, particularly at moderate capacity (40%), where it achieved a net benefit gain of +0.106 (Table 10) over the next best approach. This aligns with decision curve analysis (DCA) results, which showed Stage 2 models offering higher net benefit than Stage 1 across clinically relevant thresholds (0.15-0.5). The finding reinforces recent evidence that incorporating model uncertainty into triage logic can mitigate the risks of over or under-treatment in constrained settings [28] Vickers & Elkin, 2006).

The conformal prediction framework achieved overall coverage of 94.5% with an abstention rate of 41.3%, ensuring that nearly all true labels were included in the model's prediction sets while flagging high-uncertainty cases. Subgroup analysis showed coverage remained above 88% for all age quartiles and BMI categories, though abstention rates were higher in extreme BMI groups (e.g., 75% for obese participants). This demonstrates the framework's ability to maintain safety guarantees across heterogeneous patient groups, echoing findings from prior work on conformal methods in medical AI [27] Angelopoulos & Bates, 2022).

These results show the importance of deployable fairness and interpretability alongside raw model performance. Coverage and abstention stratified by age and BMI revealed that older and underweight groups exhibited higher abstention rates, indicating potential equity concerns in real-world screening. This insight, enabled by conformal prediction, allows for targeted workflow adjustments for instance, supplementing automated predictions with clinician review for subgroups more prone to abstention. The implications extend to AI governance frameworks advocating transparency, subgroup analysis and calibrated probability estimates before clinical adoption [57] Topol, 2019, [58] Wiens et al., 2019). By combining model calibration, decision-analytic validation and operational constraints into the evaluation, our approach advances the conversation from whether a model is accurate to how it can be deployed responsibly under real-world resource limits.

A major contribution of this work is the demonstration that targeted, data-driven feature selection can enhance performance without significantly increasing acquisition cost. Feature importance and drop-sensitivity analysis revealed that up to 90% of the maximum achievable AUC could be retained with lesser top-ranked features. This finding supports the feasibility of deploying accurate yet resource-efficient models in clinical settings where costs and time for data collection are constrained. Another contribution lies in the integration of uncertainty aware triage strategies. By incorporating model confidence into the selection process, this policy achieved higher net benefit than both risk-only and utility-based approaches under varying capacity constraints. This is particularly relevant for operational scenarios where not all patients can be assessed immediately and prioritisation must balance efficiency and accuracy.

The addition of a conformal prediction layer further improved safety and interpretability. At optimal threshold α = 0.05, the framework maintained high coverage across all age and BMI subgroups while abstaining from overly uncertain predictions. This ensures that model uncertainty is transparently communicated and provides clinicians with a mechanism to defer decisions in ambiguous cases. The novelty of this study is in its unified integration of cost-effective feature optimisation, confidence-informed triage and calibrated uncertainty quantification into a single, validated pipeline. While these elements have been explored separately in prior research, their combined evaluation and synergy in a capacity-constrained, safety-critical context provides a new and practical template for real-world clinical AI deployment [41] Vovk et al., 2022, [29] Van Calster et al., 2019).

The dataset size was relatively modest (n = 541), which may limit the generalisability of subgroup findings, particularly for rare BMI categories. External validation on larger, more diverse cohorts will be essential, with enriched demographic information. In addition, the operational simulations were based on retrospective data; prospective studies will be needed to evaluate the impact of these strategies on real-world outcomes. Future work could explore integrating temporal dynamics, richer socio-demographic features and adaptive learning to further optimise both accuracy and fairness over time.

5.0 Conclusion

This study presents a cost-efficient, deployable AI framework that integrates feature selection, uncertainty awareness triage and conformal prediction to enhance PCOS diagnostic decision-making under operational constraints. By augmenting baseline models with a small set of additional, low-cost features, Stage 2 configurations achieved substantial gains in discrimination, calibration and clinical net benefit, as confirmed by statistical comparisons and decision curve analysis. The proposed uncertainty aware triage strategy further improved net benefit at constrained capacities, while the conformal prediction layer provided high coverage with transparent abstention rates across demographic subgroups.

Beyond accuracy, the framework demonstrates how predictive models can be evaluated and optimized for real-world healthcare settings, addressing both performance and equitable deployment. These findings support the translation of AI-based screening tools from research to practice, particularly in resource-limited contexts where diagnostic capacity must be balanced against reliability and fairness.

Funding

This work received no funding.

Competing Interests

The authors declare no competing interests. The work was conducted independently, not on behalf of our current or past affiliations.

Data and Code Availability

The datasets analyzed during the current study is publicly available at Kaggle (https://www.kaggle.com/datasets/prasoonkottarathil/polycystic-ovary-syndrome-pcos/data). The code supporting the findings of this study is available from the corresponding author on reasonable request.

References

[1] Lizneva, D., Suturina, L., Walker, W., Brakta, S., Gavrilova-Jordan, L., & Azziz, R. (2016). Criteria, prevalence and phenotypes of polycystic ovary syndrome. Fertility and sterility, 106(1), 6-15. https://doi.org/10.1016/j.fertnstert.2016.05.003

[2] Shukla A, Rasquin LI, Anastasopoulou C. Polycystic Ovarian Syndrome. 2025 Jul 7. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. PMID: 29083730.

[2] D'Souza, Pramila & Rodrigues, Devina & Kaipangala, Raja & KC, Leena & Dalmeida, Joylene. (2022). Correlation between the Physical Signs, Clinical Parameters and the Quality of Life in Young Women with Polycystic Ovarian Syndrome: An Explorative Study. Journal of South Asian Federation of Obstetrics and Gynaecology. 14. 17-21. DOI: 10.5005/jp-journals-10006-1993.

[3] Tay, C. T., Garrad, R., Mousa, A., Bahri, M., Joham, A., & Teede, H. (2023). Polycystic ovary syndrome (PCOS): international collaboration to translate evidence and guide future research. Journal of Endocrinology, 257(3), e220232. Retrieved Oct 2, 2025, from https://doi.org/10.1530/JOE-22-0232

[4] Arghavan Ghafari, Malihe Maftoohi, Mohammadamin Eslami Samarin, Sepideh Barani, Majid Banimohammad, Reza Samie. The last update on polycystic ovary syndrome (PCOS), diagnosis criteria and novel treatment, Endocrine and Metabolic Science, Volume 17, (2025), 100228, ISSN 2666-3961, https://doi.org/10.1016/j.endmts.2025.100228.

[5] Long C, Feng H, Duan W, Chen X, Zhao Y, Lan Y, Yue R. Prevalence of polycystic ovary syndrome in patients with type 2 diabetes: A systematic review and meta-analysis. Front Endocrinol (Lausanne). 2022 Aug 31;13:980405. doi: 10.3389/fendo.2022.980405. PMID: 36120432; PMCID: PMC9471325.

[6] Ramadan S. Hussein, Salman Bin Dayel, Othman Abahussein. Polycystic Ovary Syndrome and Reproductive Health: A Comprehensive Review. Clin.

Exp. Obstet. Gynecol. 2024, 51(12), 269. DOI: 10.31083/j.ceog5112269

[7] Barrera FJ, Brown EDL, Rojo A, Obeso J, Plata H, Lincango EP, Terry N, Rodríguez-Gutiérrez R, Hall JE and Shekhar S (2023) Application of machine learning and artificial intelligence in the diagnosis and classification of polycystic ovarian syndrome: a systematic review. Front. Endocrinol. 14:1106625. doi: 10.3389/fendo.2023.1106625

[8] Vazquez J, Facelli JC. Conformal Prediction in Clinical Medical Sciences. J Healthc Inform Res. 2022 Jan 28;6(3):241-252. doi: 10.1007/s41666-021-00113-8. PMID: 35898853; PMCID: PMC9309105.

[9] Xu X, Jiang Y, Du J, Sun H, Wang X, Zhang C. Development and validation of a prediction model for suboptimal ovarian response in polycystic ovary syndrome (PCOS) patients undergoing GnRH-antagonist protocol in IVF/ICSI cycles. J Ovarian Res. 2024 May 28;17(1):116. doi: 10.1186/s13048-024-01437-w. PMID: 38807145; PMCID: PMC11134646.

[10] Zad, Z. et al. "Predicting polycystic ovary syndrome with machine learning algorithms from electronic health records." Frontiers in Endocrinology (2024). https://doi.org/10.3389/fendo.2024.1298628

[11] Suha, S. et al. "Machine learning for early detection of polycystic ovary syndrome using ultrasound image analysis." Scientific Reports 12, 21817 (2022). https://doi.org/10.1038/s41598-022-21724-0

[12] Abdelsalam, S.H. et al. "Optimized polycystic ovarian disease prognosis and classification using modern AI multi-modality approaches." BMC Medical Informatics and Decision Making 24, 256 (2024). https://doi.org/10.1186/s12911-024-02577-8

[13] Agirsoy, M.; Oehlschlaeger, M.A. "A machine learning approach for non-invasive PCOS diagnosis from ultrasound and clinical features." Scientific Reports 15:33638, 2025. DOI: 10.1038/s41598-025-10453-9.

[14] Zigarelli, A.; Jia, Z.; Lee, H. "Machine-Aided Self-diagnostic Prediction Models for Polycystic Ovary Syndrome: Observational Study." JMIR Formative Research 6(3):e29967 (2022). https://doi.org/10.2196/29967

[15] Shanmugavadivel, K., M S, M.D., T R, M. et al. Optimized polycystic ovarian disease prognosis and classification using AI based computational approaches on multi-modality data. BMC Med Inform Decis Mak 24, 281 (2024). https://doi.org/10.1186/s12911-024-02688-9

[16] Tong, C.; Wu, Y.; Zhuang, Z.; Yu, Y. "A diagnostic model for polycystic ovary syndrome based on machine learning." Scientific Reports 15:9821, 2025. DOI: 10.1038/s41598-025-92630-4.

[17] Polycystic Ovary Syndrome (PCOS) - Kaggle (Kerala dataset, 541 patients)." Accessed 24th July 2025. https://www.kaggle.com/datasets/prasoonkottarathil/polycystic-ovary-syndrome-pcos/data

[18] Khanna, V.V. et al. "A Distinctive Explainable Machine Learning Framework for Detection of Polycystic Ovary Syndrome." Applied System Innovation 6(2):32 (2023). https://doi.org/10.3390/asi6020032

[19] Rahman, M.M. et al. "Empowering Early Detection: A Web-Based Machine Learning Approach for PCOS Prediction." Informatics in Medicine Unlocked 47:101500 (2024). https://doi.org/10.1016/j.imu.2024.101500

[20] Taha, R.; Zain El Abdin, H.; Musleh, T. "Comparative Analysis of Supervised Machine Learning Models for PCOS Prediction Using Clinical Data." Journal of Engineering Research and Sciences 4(6):16-26, 2025. DOI: 10.55708/js0406003.

[21] Tiwari, S. et al. "SPOSDS: A Smart Polycystic Ovary Syndrome Diagnostic System Using Machine Learning." Expert Systems with Applications 203:117592 (2022). https://doi.org/10.1016/j.eswa.2022.117592

[22] Danaei Mehr, H.; Polat, H. "Diagnosis of polycystic ovary syndrome through different machine learning and feature selection techniques." Health and Technology 12, 137-150 (2022). https://doi.org/10.1007/s12553-021-00613-y

[23] Bharati, S.; Podder, P.; Mondal, M.R.H. "Diagnosis of Polycystic Ovary Syndrome Using Machine Learning Algorithms." 2020 IEEE Region 10 Symposium (TENSYMP) (2020). https://doi.org/10.1109/TENSYMP50017.2020.9230932

[24] Mohi Uddin, K.M.; Bhuiyan, M.T.A.; Rahman, M.M.; Islam, M.M.; Uddin, M.A. "Early PCOS Detection: A Comparative Analysis of Traditional and Ensemble Machine Learning Models With Advanced Feature Selection." Engineering Reports 7(2):e70008, 2025. DOI: 10.1002/eng2.70008.

[25] Panjwani, B.; Yadav, J.; Mohan, V.; Agarwal, N.; Agarwal, S. "Optimized Machine Learning for the Early Detection of Polycystic Ovary Syndrome in Women." Sensors 25(4):1166, 2025. DOI: 10.3390/s25041166.

[26] Emara, H.M.; El-Shafai, W.; Soliman, N.F.; Algarni, A.D.; Alkanhel, R.; Abd El-Samie, F.E. "A stacked learning framework for accurate classification of polycystic ovary syndrome with advanced data balancing and feature selection techniques." Frontiers in Physiology 16:1435036, 2025. DOI: 10.3389/fphys.2025.1435036.

[27] Angelopoulos, A.N.; Bates, S. "Conformal Prediction: A Gentle Introduction." Foundations and Trends in Machine Learning 16(4):494-591 (2022). https://doi.org/10.1561/2200000101

[28] Vickers, A.J.; Elkin, E.B. "Decision Curve Analysis: A Novel Method for Evaluating Prediction Models." Medical Decision Making 26(6):565-574 (2006). https://doi.org/10.1177/0272989X06295361

[29] Van Calster, Ben & Mclernon, David & van Smeden, Maarten & Wynants, Laure & Steyerberg, Ewout. (2019). Calibration: The Achilles heel of predictive analytics. BMC Medicine. 17. DOI:10.1186/s12916-019-1466-7.

[30] Moons KG, Altman DG, Reitsma JB, Ioannidis JP, Macaskill P, Steyerberg EW, Vickers AJ, Ransohoff DF, Collins GS. Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration. Ann Intern Med. 2015 Jan 6;162(1):W1-73. doi: 10.7326/M14-0698. PMID: 25560730.

[31] Steyerberg, E. W. (2019). Clinical Prediction Models: A Practical Approach to Development, Validation and Updating (2nd ed.). Springer. DOI: 10.1007/978-3-030-16399-0.

[32] Moons KG, Altman DG, Vergouwe Y, Royston P. Prognosis and prognostic research: application and impact of prognostic models in clinical practice. BMJ. 2009 Jun 4;338:b606. doi: 10.1136/bmj.b606. PMID: 19502216.

[33] Olsson, H., Kartasalo, K., Mulliqi, N. et al. Estimating diagnostic uncertainty in artificial intelligence assisted pathology using conformal prediction. Nat Commun 13, 7761 (2022). https://doi.org/10.1038/s41467-022-34945-8

[34] Zhang Z. Missing data imputation: focusing on single imputation. Ann Transl Med. 2016 Jan;4(1):9. doi: 10.3978/j.issn.2305-5839.2015.12.38. PMID: 26855945; PMCID: PMC4716933.

[35] Breiman, L. (2001). Random forests. Machine Learning, 45(1), 5-32. https://doi.org/10.1023/A:1010933404324

[36] Powers, David & Ailab,. (2011). Evaluation: From precision, recall and F-measure to ROC, informedness, markedness & correlation. J. Mach. Learn. Technol. 2. 2229-3981. DOI 10.9735/2229-3981.

[37] Brier, G. W. (1950). Verification of forecasts expressed in terms of probability. Monthly Weather Review, 78(1), 1-3

[38] Naeini, M. P., Cooper, G. F., & Hauskrecht, M. (2015). Obtaining well calibrated probabilities using Bayesian binning. AAAI Conference on Artificial Intelligence.

[39] Altmann, A., Toloşi, L., Sander, O., & Lengauer, T. (2010). Permutation importance: a corrected feature importance measure. Bioinformatics, 26(10), 1340-1347. https://doi.org/10.1093/bioinformatics/btq134

[40] Kaufman, S., Rosset, S., Perlich, C., & Stitelman, O. (2012). Leakage in data mining: Formulation, detection and avoidance. ACM Transactions on Knowledge Discovery from Data, 6(4), 1-21.

[41] Vovk, V., Gammerman, A., & Shafer, G. (2022). Algorithmic Learning in a Random World. Springer Science & Business Media. DOI:10.1007/978-3-031-06649-8

[42] Shafer, G., & Vovk, V. (2008). A tutorial on conformal prediction. Journal of Machine Learning Research, 9(Mar), 371-421.

[43] Rina Foygel Barber, Emmanuel J. Candès, Aaditya Ramdas, Ryan J. Tibshirani "Predictive inference with the jackknife+," The Annals of Statistics, Ann. Statist. 49(1), 486-507, (February 2021)

[44] Clopper, C. J., & Pearson, E. S. (1934). The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika, 26(4), 404-413.

[45] DeLong, E. R., DeLong, D. M., & Clarke-Pearson, D. L. (1988). Comparing the areas under two or more correlated receiver operating characteristic curves: A nonparametric approach. Biometrics, 44(3), 837-845.

[46] Wasserstein, R. L., Schirm, A. L., & Lazar, N. A. (2019). Moving to a World Beyond "p < 0.05". The American Statistician, 73(sup1), 1-19.

[47] Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. BMJ. 2015 Jan 7;350:g7594. doi: 10.1136/bmj.g7594. PMID: 25569120.

[48] Tom Fawcett, An introduction to ROC analysis, Pattern Recognition Letters, Volume 27, Issue 8, 2006, Pages 861-874, ISSN 0167-8655, https://doi.org/10.1016/j.patrec.2005.10.010.

[49] Noroozi, Z., Orooji, A., & Erfannia, L. (2023). Analyzing the impact of feature selection methods on machine learning algorithms for heart disease prediction. Scientific Reports, 13, 22588. https://doi.org/10.1038/s41598-023-49962-w

[50] Cutler, D. R., Edwards, T. C., Jr, Beard, K. H., Cutler, A., Hess, K. T., Gibson, J., & Lawler, J. J. (2007). Random forests for classification in ecology. Ecology, 88(11), 2783-2792. https://doi.org/10.1890/07-0539.1

[51] García-Carretero, R., Holgado-Cuadrado, R., & Barquero-Pérez, Ó. (2021). Assessment of Classification Models and Relevant Features on Nonalcoholic Steatohepatitis Using Random Forest. Entropy, 23(6), 763. https://doi.org/10.3390/e23060763

[52] Alexandru Niculescu-Mizil and Rich Caruana. 2005. Predicting good probabilities with supervised learning. In Proceedings of the 22nd international conference on Machine learning (ICML '05). Association for Computing Machinery, New York, NY, USA, 625-632. DOI:10.1145/1102351.1102430

[53] Vickers, A.J., van Calster, B. & Steyerberg, E.W. A simple, step-by-step guide to interpreting decision curve analysis. *Diagn Progn Res* **3**, 18 (2019). https://doi.org/10.1186/s41512-019-0064-7

[54] El-Yaniv, R., & Wiener, Y. (2010). On the Foundations of Noise-free Selective Classification. *J. Mach. Learn. Res., 11*, 1605-1641. {No DOI}

[55] Desautels T, Calvert J, Hoffman J, Jay M, Kerem Y, Shieh L, Shimabukuro D, Chettipally U, Feldman MD, Barton C, Wales DJ, Das R. Prediction of Sepsis in the Intensive Care Unit With Minimal Electronic Health Record Data: A Machine Learning Approach. JMIR Med Inform. 2016 Sep 30;4(3):e28. doi: 10.2196/medinform.5909. PMID: 27694098; PMCID: PMC5065680.

[56] Shim H., Hwang S.J., Yang E., 2018. "Joint Active Feature Acquisition and Classification with Variable-Size Set Encoding." 32nd Conference on Neural Information Processing Systems (NeurIPS 2018), Montréal, Canada..

[57] Topol, Eric J.. "High-performance medicine: the convergence of human and artificial intelligence."

Nature Medicine 25 (2019): 44 - 56. DOI:10.1038/s41591-018-0300-7

[58] Wiens J, Saria S, Sendak M, Ghassemi M, Liu VX, Doshi-Velez F, Jung K, Heller K, Kale D, Saeed M, Ossorio PN, Thadaney-Israni S, Goldenberg A. Do no harm: a roadmap for responsible machine learning for health care. Nat Med. 2019 Sep;25(9):1337-1340. doi: 10.1038/s41591-019-0548-6. Epub 2019 Aug 19. Erratum in: Nat Med. 2019 Oct;25(10):1627. doi: 10.1038/s41591-019-0609-x. PMID: 31427808.